AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06784128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hot Pack
Description: As part of the treatment protocol, a hot pack was applied to the affected shoulder area for 30 minutes prior to any other therapeutic interventions. This initial application of heat was intended to promote muscle relaxation, increase local blood circulation, and reduce joint stiffness, effectively preparing the shoulder for the subsequent treatments, including therapeutic exercise, TENS and TECAR therapy. The hot pack was maintained at a temperature between 40-45°C, which is considered optimal for achieving therapeutic heat without causing discomfort or skin irritation.
Study NCT06784128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TECAR Therapy
Description: TECAR therapy was administered using the BTL-6000 TR-Therapy PRO device which emitted energy at a frequency of approximately 500 kHz and used three types of electrodes: active, neutral, and static application electrodes. Each patient was seated in a comfortable position with the affected shoulder exposed, ensuring adequate support and stability throughout the treatment session. The affected shoulder was prepared with a conductive gel to enhance energy transfer. During the session, the capacitive electrode was initially applied, targeting the superficial muscles and tendons around the shoulder joint using circular or linear movements for 5 min. Following this, the resistive electrode was employed to target deeper structures, focusing on the joint capsule and rotator cuff muscles for 10 min. The output power was adjusted based on the patient's tolerance, ensuring a comfortable warm sensation without causing discomfort or burning feeling or pain.
Study NCT06784128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS was employed as a non-invasive pain management technique in this study, utilizing the Intellect Advanced device manufactured by Chattanooga Group. Electrodes were strategically placed over the affected shoulder, ensuring coverage of the most painful areas as well as relevant nerve pathways to maximize the analgesic effect. A symmetric biphasic waveform was selected, with a frequency of 100 Hz and a pulse duration of 100 microseconds. The intensity of the stimulation was adjusted according to the patient's tolerance, typically aiming for a strong, yet comfortable tingling sensation.
Study NCT06784128 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS was employed as a non-invasive pain management technique in this study, utilizing the Intellect Advanced device manufactured by Chattanooga Group. Electrodes were strategically placed over the affected shoulder, ensuring coverage of the most painful areas as well as relevant nerve pathways to maximize the analgesic effect. A symmetric biphasic waveform was selected, with a frequency of 100 Hz and a pulse duration of 100 microseconds. The intensity of the stimulation was adjusted according to the patient's tolerance, typically aiming for a strong, yet comfortable tingling sensation.
Study NCT06792461 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity and nutritional behavioural intervention
Description: Digital eHealth platform to improve physical activity levels and dietary habits
Study NCT06789705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: MDMA will be administered in a single dose of 50 mg (2 capsules of 25 mg MDMA) or 25mg (1 capsule of 25 mg MDMA, 1 capsule containing only mannitol filler) and given at treatment visit.
Study NCT06789705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be prepared as identical gelatin capsules containing only mannitol filler and given at treatment visit.
Study NCT06789198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccination of Fusion-VAC-XS15
Description: FusionVAC-22 peptide will be administered subcutaneously (s.c.) with the TLR1/2 ligand XS15 (50 µg) emulsified in Montanide ISA 51 VG (1:1).~A total of two vaccinations are planned, 4 weeks apart from each other. If no sufficient T cell response is achieved at the end of treatment visit (28 days after last vaccination) a booster vaccination at day 56 (+7 days) after the second vaccination can be applied
Study NCT04815161 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adherence
Description: Adherence to medication using an electronic pillbox
Study NCT05908513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: Will be used as capsule form, 600mg per day if the patient can tolerate it. If not, we may decrease the dosage.
Study NCT05908513 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar chemical structure of NAC but without function
Study NCT04872738 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Patients in all groups will complete surveys about their decision to receive or not to receive the COVID-19 vaccine. For those who did receive the vaccine, they will indicate their experience with the vaccination and any side effects they may have experienced.
Study NCT04453020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS of the LHA
Description: Deep Brain Stimulation of the Lateral Hypothalamic Area
Study NCT06056102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: * Safety Run-in: 375mg/m\^2 daily x 3~* Cohort 1: 375mg/m\^2 daily x 3~* Cohort 2: 375mg/m\^2 daily x 3~* Cohort 3: 375mg/m\^2 daily x 3
Study NCT06056102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-BCMA
Description: * Safety Run-in: 5 x 10\^7 CAR T cells~* Cohort 1: 1.5 x 10\^8 CAR T cells~* Cohort 2: 1.5 x 10\^8 CAR T cells~* Cohort 3: 5 x 10\^8 CAR T cells
Study NCT06056102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19
Description: * Safety Run-in: 5 x 10\^7 CAR T cells~* Cohort 1: 1.5 x 10\^8 CAR T cells~* Cohort 2: 1.5 x 10\^8 CAR T cells~* Cohort 3: 5 x 10\^8 CAR T cells
Study NCT06056102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: • Cohort 3: 24mg/m\^2 daily x 3
Study NCT06549946 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixovex-1
Description: Ixovex-1 is a novel oncolytic human adenovirus serotype 5.
Study NCT06549946 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanised antibody
Study NCT06226571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNDX-5613
Description: Participants will receive SNDX-5613 orally during Induction, Consolidation, and Maintenance until meeting criteria for discontinuation.
Study NCT06226571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Regimen
Description: Induction: Participants will receive an intravenous (IV), 2-drug combination of cytarabine and either daunorubicin or idarubicin.
Study NCT06226571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HiDAC
Description: Consolidation: Participants will receive HiDAC IV.
Study NCT04880863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAP (Naptumomab estafenatox)
Description: Naptumomab estafenatox (NAP; ABR-217620) is a recombinant fusion protein consisting of a chimeric staphylococcal enterotoxin A/E (SEA/SEE) superantigen with several additional substitutions that is linked to a Fab moiety recognizing a tumor-associated glycoprotein, 5T4. NAP will be administered in a dose of 10 μg/kg/day by IV bolus on Days 1 - 4 of treatment cycles 1-6. Starting cycle 7, NAP at a higher dose of 15 μg/kg will be administered on Day 1.
Study NCT04880863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is administered in combination with the study drug, NAP, on Day 5 of the treatment cycles 1-6. Starting cycle 7, Docetaxel will be administered in combination with the study drug, NAP, on Day 2.
Study NCT04880863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab is administered as pre-medication on Day -13 and -12 of the first treatment cycle.
Study NCT06000956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jitongning tablets
Description: The participants took orally three tablets of Jitongning tablets, twice a day, for 8 consecutive weeks.
Study NCT06000956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: a simulated agent of Jitongning tablets
Description: The participants took orally three tablets of a simulated agent of Jitongning tablets, twice a day, for 8 consecutive weeks.
Study NCT04216342 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fx-5A peptide complex
Description: subject will receive a slow I.V. infusion of the Fx-5A peptide complex as described in Table 1. Five to 10 mL of blood will be collected at 30min (+/- 5min\*), 1h (+/- 10min\*), 2h (+/- 10min\*), 4h (+/- 15min\*), 8h (+/- 30min\*), 12h (+/- 30min\*), and 24h (+/- 30min\*) for laboratory tests and to be stored for research tests. The patient will be dismissed, as inpatient, 24-36 hours after the beginning of the treatment.
Study NCT05152849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXA1125
Description: AXA1125 administered BID with or without food
Study NCT05152849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo administered BID with or without food
Study NCT01140100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Study NCT01140100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiopental,propofol
Study NCT05185245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Transplantation
Description: Liver Transplantation for Non-Resectable Colorectal Liver Metastasis
Study NCT05146297 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical trial match-list
Description: Creation and dissemination educational materials designed to inform and empower patients' participation in their cancer treatment including the consideration of clinical trial participation and provide clinical trials' patient navigators (CTPN) to further aid with education about clinical trials.
Study NCT05146297 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Match-list intervention
Description: Providers by intervening at the clinical and systems levels to provide them with tools and processes and informational and practical support to facilitate CT consideration, discussion, and offer to aid with education about clinical trials and facilitate CT consideration at a treatment decision node.
Study NCT05612373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID Booster text messages
Description: Participants will receive text messages per descriptions listed in the arms.
Study NCT04868994 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole Body MRI and ENMG
Description: Whole body muscle MRI lasting 30 to 45 min without injection of contrast medium an ENMG
Study NCT03981757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeurOS
Description: NeurOS system pads will be placed on patients' head for monitoring.
Study NCT06166459 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon combined with provisional drug-eluting stent implantation
Description: (1) DCB combined with provisional DES implantation 1-2 mm distally to the ostium lesion whenever this was required (DCB+pDES strategy). (2) DES implantation 1-2 mm distally to the ostium lesions followed by DCB treatment (DES+DCB strategy).
Study NCT06208293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KPZ Program (KPZ)
Description: The KPZ package includes a culturally adapted approach to a co-designed safety plan. The assigned Peers will provide safety planning and Brief Contact Follow-Up. Contact follow up sessions will occur at the household level.
Study NCT06208293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Participants receive usual care enhanced by Lady Health Workers (LHWs) trained in WHO Mental Health Gap Action Programme (mhGAP) that will link at-risk women with the primary care facility based medical officer. The LHWs will follow the mhGAP protocol for imminent or low risk of suicide including ensuring the participant is safe, removing or reducing means, assigning a family member to ensure safety (if appropriate), providing psychoeducation, and referring and accompanying the individual to their primary care health center where a mhGAP trained doctor is staffed to resume care or make a referral to specialized care. Additionally, all women and healthcare workers are provided a 24 hour hotline number (hosted by a Pakistani based mental health organization called Taskeen) and are briefed on exactly what will happen if participant calls.
Study NCT06208293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care (EUC)
Description: Participants receive usual care enhanced by Lady Health Workers (LHWs) trained in WHO Mental Health Gap Action Programme (mhGAP) that will link at-risk women with the primary care facility based medical officer. The LHWs will follow the mhGAP protocol for imminent or low risk of suicide including ensuring the participant is safe, removing or reducing means, assigning a family member to ensure safety (if appropriate), providing psychoeducation, and referring and accompanying the individual to their primary care health center where a mhGAP trained doctor is staffed to resume care or make a referral to specialized care. Additionally, all women and healthcare workers are provided a 24 hour hotline number (hosted by a Pakistani based mental health organization called Taskeen) and are briefed on exactly what will happen if participant calls.
Study NCT04823923 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling for ITK dosage
Description: Blood sample for ITK dosage at visit 1 (1 month +/- 1 week after the start of treatment) and at visit 2 (3 months +/- 1 month after the start of treatment)
Study NCT05422495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training with Cycléo device (COTTOS ®),
Description: 8 weeks of training
Study NCT05422495 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non intervention
Description: non intervention
Study NCT05984186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Velocity Therapy
Description: FiO2=100% with Flow=5LPM FiO2=21% with Flow=25-35LPM FiO2=100% with Flow=25-35LPM FiO2=21% with Flow=5LPM
Study NCT05342012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Concentrated beetroot juice
Description: Acute and chronic supplementation of beetroot juice.
Study NCT05342012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate depleted beetroot juice
Description: (Nitrate depleted beetroot juice
Study NCT05867420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASKG915
Description: ASKG915 is administered intravenously at a fixed dose. The drug was given once every 3 weeks for a cycle.
Study NCT04989816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Trastuzumab deruxtecan (T-DXd) by intravenous infusion
Study NCT05180838 — intervention group
Intervention type: DEVICE
Intervention: BioSticker
Description: The BioSticker is an FDA approved medical device which can be worn on the upper left chest for remote data capture and can provide for up 30 days of continuous vital sign monitoring
Study NCT04798261 — intervention group
Intervention type: DEVICE
Intervention: Indigo Aspiration System
Description: Indigo Aspiration System
Study NCT06513507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabigerol (CBG)
Description: The daily dose will consist of 50 mg of CBG. Blood tests will be conducted at Baseline, Week 2, Week 4, Week 6, and Week 8 to monitor inflammatory markers and immune response. Self-reported questionnaires will be completed at Baseline, Week 4, and Week 8 to assess symptoms and quality of life.
Study NCT05562427 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Gold-Standard Online Behavioral Obesity Treatment
Description: Rx Weight Loss (RxWL) is an online BOT that consists of: (a) tailored weight loss, calorie, and physical activity goals. (b) 12 weekly 10-15 minute multimedia lessons for training in behavioral weight loss skills followed by 9 monthly lessons for continued weight loss. Lessons incorporate video, animation, audio, quizzes, and exercises for goal setting, planning, and problem-solving. Example topics include restaurant eating, changing the home environment, and obtaining social support. (c) Online tools for self-monitoring weight, diet, and physical activity that interface with popular tracking apps; and (c) Weekly, and eventually monthly, automated feedback on progress to date (delivered as text appearing on the platform). If goals are not met participants receive strategies to improve weight loss, along with encouragement. To ensure engagement, email reminders are sent to participants who have not visited the platform on a given week.
Study NCT04905797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Emotional Stop Signal Task
Description: Emotional Stop Signal Task (modified version from CANTAB). Outcome Measure is commission and omission errors - higher score (percentage) indicate worse performance.
Study NCT04905797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Functional Magnetic Resonance Imaging (fMRI) Diffusion Tensor Imaging (DTI) Volumetry
Study NCT05533281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tropisetron
Description: One tropisetron was given 30 minutes in advance, and then tramadol 1.5mg/kg was intravenously injected with a micropump at a constant speed.
Study NCT05533281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide
Description: One dose of metoclopramide was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
Study NCT05533281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: One dose of dexamethasone was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
Study NCT05533281 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Equal dose of normal saline was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
Study NCT04800705 — intervention group
Intervention type: OTHER
Intervention: ultrasound assessment
Description: Zinc (Zn), copper (Cu), calcium (Ca), iron (Fe), manganese (Mn), selenium (Se), strontium (Sr), aluminum (Al), antimonium (Sb), phosphorus (P), magnesium (Mg), sodium (Na), potassium (K), barium (Ba) and thallium (Tl) measurements (µg/L,mean±SD)
Study NCT05627960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-01 Compound
Description: Phase 1A dose escalation study: enrolled subjects with advanced solid tumors will receive AG-01 compound at various doses.~Phase 1B patients will be treated with AG-01 at the RP2D.
Study NCT05241106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYML-122
Description: each treatment cycle is comprised of 28-day consecutive dosing of HYML-122. Upon completion of each cycle, patients may continue to receive oral HYML-122 tablets if they are benefit from the treatment and the toxicity is tolerable.
Study NCT04953546 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is an observation study, with no intervention
Study NCT05131646 — intervention group
Intervention type: DRUG
Intervention: CLS-AX
Description: injectable suspension of small molecule tyrosine kinase inhibitor (TKI) administered in the Parent study CLS1002-101
Study NCT04907656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dCBT
Description: As per arm of the same name
Study NCT04826107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c treatment
Description: DP303c injection, every 3 weeks.
Study NCT04826107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c treatment（second-line of HER2-positive）
Description: DP303c injection, every 3 weeks.
Study NCT04826107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c treatment （third-line of HER2-positive）
Description: DP303c injection, every 3 weeks.
Study NCT04826107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c treatment（≥second-line of HER2 low expressing）
Description: DP303c injection, every 3 weeks.
Study NCT04826107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c + PD-1/PD-L1 treatment
Description: DP303c injection + PD-1/PD-L1 injection, dose and frequency to be determined.
Study NCT05195437 — intervention group
Intervention type: OTHER
Intervention: QoLiSSY and PedsQL 4.0 questionnaires
Description: Patients have been reaching adult size complete the two questionnaires of the study :~Quality of Life of Short Stature Youth questionnaire (QoLiSSY), assessing health-related quality of life in short stature youth.~Pediatric Quality of Life Inventory (PedsQL) 4.0 : general health-related quality of life.~The patients have previously completed the PedsQL 4.0 and QoLiSSY questionnaires when starting their growth hormone therapy and after one year of growth hormone therapy.
Study NCT05611645 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Stereotactic Radiotherapy
Description: Starting with low-dose bevacizumab, 25Gy in 5 fractions of 5 Gy each delivered on consecutive treatment days.
Study NCT05611645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Staring within 2 weeks of randomization, IV 5mg/kg (experimental group) or 10mg/kg (comparison group) every two weeks until disease progression.
Study NCT05611645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Staring within 2 weeks of randomization, IV 5mg/kg (experimental group) or 10mg/kg (comparison group) every two weeks until disease progression.